Poseida Therapeutics, Inc. (NASDAQ: PSTX) reported Q1 EPS of ($0.25), $0.17 better than the analyst estimate of ($0.42). Revenue for the quarter came in at $28.14 million versus the consensus estimate of $10.03 million.

For earnings history and earnings-related data on Poseida Therapeutics, Inc. (PSTX) click here.